Want to join the conversation?
During 3Q15, $JNJ filed for Marketing Authorization in Europe for daratumumab, a treatment for patients with relapsed/refractory multiple myeloma, which received accelerated assessment from the CHMP. Daratumumab was granted Priority Review in the US. $JNJ submitted a SNDA to US FDA for IMBRUVICA for treatment of naive chronic lymphocytic leukemia.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.